Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZR-MD-001 in MGD and Evaporative DED
NCT03652051Phase 2Completed
- Sponsor
- Azura Ophthalmics
- Start
- Sep 2018
- Primary completion
- Sep 2022
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial of selenium sulfide ophthalmic ointment in meibomian gland dysfunction (MGD) and dry eye disease (DED) (4 arms), sponsored by Azura Ophthalmics. Primary endpoints: Meibomian Glands Yielding Liquid Secretion at 3 months and Ocular Surface Disease Index at 3 months. Started Sep 2018; status: completed.
02
Drugs
selenium sulfide ophthalmic ointment
03
Conditions
meibomian gland dysfunction (MGD)dry eye disease (DED)
Beyond the preview
Go deeper on NCT03652051.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03652051.